Abstract: There is disclosed a drug-monoclonal antibody conjugate wherein the antibody is linked to a antitumor drug using disulfide benzyl carbamate or carbonate as the linker. Also disclosed is a method of delivering an active antitumor drug to the site of tumor cells in a mammal by administering the drug-monoclonal antibody conjugate.
Abstract: A platinum co-ordination compound linkable to a monoclonal antibody by a functional group which forms part of a moiety which stabilizes the antibody against in vivo hydrolysis. Also the use of such compounds in the treatment of cancer.
Type:
Grant
Filed:
July 20, 1988
Date of Patent:
August 28, 1990
Assignee:
Johnson Matthey PLC
Inventors:
James G. Heffernan, Michael J. Cleare, Donald H. Picker
Abstract: A new method is described for eliciting IgG antibody response to proteins or synthetic peptides without the requirement for the use of adjuvants, thereby making it easier and safer to confer protection against pathogenic organisms. The antigen is coupled to a monoclonal antibody, specific for membrane determinants expressed on certain types of mammalian recipient cells, called antigen presenting cells. The monoclonal antibody acts as a "vector" or "delivery vehicle" for targeting foreign antigens onto such recipient cells. This targeting facilitates subsequent antigen recognition by helper T-cells, which are pivotal in helping the induction of antigen-specific IgG responses.
Abstract: A protein conjugate or mixture useful in immunotherapy composed of a biological response modifier (BRM) and an allergen is disclosed. In use the protein conjugate or mixture is combined with a pharmaceutically acceptable carrier. Cytokines, bacterial, fungal and viral immunopotentiators and thymus hormones are disclosed as suitable BRM's for use in the invention.
Abstract: Novel methods and compositions are provided for the enhancement of the biodistribution of immunoconjugates useful in the diagnosis and treatment of a variety of conditions including cancer in many of its forms. The compositions of the present invention provide for enhanced bioavailability of immunoconjugates for the most part by blocking mammalian cell surface receptors present on cells of the reticuloendothelial system, especially in tissues responsible for the elimination of waste products and blood filtration. Such tissues include the liver, spleen, and kidneys. The compositions are administered in conjunction with an immunoconjugate in a pharmaceutically acceptable vehicle and may be provided in kits for convenient administration.
Abstract: A method of reducing tissue injury in humans or other animal species using a monoclonal antibody to inhibit specific phagocyte functions. The monoclonal antibody is selected to bind to phagocytic leukocytes for the purpose of inhibiting migration to an inflammatory site in the body and to inhibit the adhesion and spreading of activated leukocytes reaching such an area and then, block release of toxic substances by these cells. The monoclonal antibody is administered in vivo prior or early in the course of an experience leading to an injurious inflammatory response such as can result from restoration of myocardial blood flow interrupted by an acute coronary thrombosis.
Type:
Grant
Filed:
March 7, 1988
Date of Patent:
June 19, 1990
Assignee:
Dana-Farber Cancer Institute
Inventors:
Robert F. Todd, III, Paul J. Simpson, Benedict R. Lucchesi, Stuart F. Scholossman, James D. Griffin
Abstract: Monoclonal antibodies demonstrating reactivity to genus-specific epitopes present on outer membrane proteins of bacteria of the genus Legionella and hybridomas for secreting the antibodies are disclosed.
Type:
Grant
Filed:
May 31, 1988
Date of Patent:
June 5, 1990
Assignee:
The University of Tennesse Research Corporation
Inventors:
Paul S. Hoffman, Leta O. Helsel, William F. Bibb, Roger M. McKinney
Abstract: A method is disclosed for stimulating the immune system of a warm-blooded animal by the production of antibodies by administering an effective amount of Cytophaga allerginae lipopolysaccharide endotoxin.
Abstract: A method for stabilizing rubella HA antigen which comprises adjusting a rubella HA antigen suspension at pH 9.6 or higher, and more preferably, concurrently adding sodium azide thereto, or adding sodium azide alone at a concentration of 1 to 10% (w/v) thereto without the above adjustment of pH.